Cargando…

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Cetuximab is a widely used drug for treating head and neck squamous cell carcinomas (HNSCCs); however, it provides restricted clinical benefits, and its response duration is limited by drug resistance. Here, we conducted randomized “Phase II-like clinical trials” of 49 HNSCC PDX models and reveal mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yanli, Wang, Yujue, Chen, Lan, Tian, Zhen, Yang, Guizhu, Wang, Rui, Wang, Chong, Wu, Qi, Wu, Yaping, Gao, Jiamin, Kang, Xindan, Duan, Shengzhong, Zhang, Zhiyuan, Sun, Shuyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904860/ https://www.ncbi.nlm.nih.gov/pubmed/35260570 http://dx.doi.org/10.1038/s41392-022-00908-0

Ejemplares similares

A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models
por: Wu, Qi, et al.
Publicado: (2023)

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020)

Single-cell and spatial dissection of precancerous lesions underlying the initiation process of oral squamous cell carcinoma
por: Sun, Lulu, et al.
Publicado: (2023)

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
por: Bray, Steven M., et al.
Publicado: (2019)

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
por: Johnson, Radia M., et al.
Publicado: (2022)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options
por: Sun, Lulu, et al.
Publicado: (2023)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
por: Huang, Jingwen, et al.
Publicado: (2016)

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
por: Liu, Qizhi, et al.
Publicado: (2021)

Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin.
por: Dolfini, E., et al.
Publicado: (1997)

Pyridoxal phosphate synthases PdxS/PdxT are required for Actinobacillus pleuropneumoniae viability, stress tolerance and virulence
por: Xie, Fang, et al.
Publicado: (2017)

Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
por: Olaitan, Abiola O., et al.
Publicado: (2014)

Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips
por: Wu, Chuntao, et al.
Publicado: (2022)

Intrinsic and acquired resistance mechanisms in enterococcus
por: Hollenbeck, Brian L., et al.
Publicado: (2012)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
por: Ingruber, Julia, et al.
Publicado: (2022)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
por: Wirth, Anna-Katharina, et al.
Publicado: (2022)

Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process
por: Chen, Chin-Fu, et al.
Publicado: (2018)

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol
por: Ritter, M., et al.
Publicado: (2016)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells
por: Cui, Jian, et al.
Publicado: (2019)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
por: Jiménez-Valerio, Gabriela, et al.
Publicado: (2016)

Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
por: Steinbichler, Teresa Bernadette, et al.
Publicado: (2015)

Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022)

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
por: Iida, Mari, et al.
Publicado: (2014)

Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies
por: Wellbrock, Claudia
Publicado: (2015)

Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma
por: Li, Xiqing, et al.
Publicado: (2018)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC
por: Yuan, Yitao, et al.
Publicado: (2023)

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis
por: Jing, Changwen, et al.
Publicado: (2019)

Antibiotic Resistance and Clonal Spread
Publicado: (2014)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ifqd46a0u4p6ucmbj7n35lbmsc